Joenja® (leniolisib) is first approved treatment in the European Union for
activated phosphoinositide 3-kinase delta (PI3K
δ
) syndrome (APDS)
, a rare primary immunodeficiency, in adult and pediatric patients aged 12 years and older
First European launch expected in Germany in Q3 2026
Approval adds to Joenja® approvals in the United States, United Kingdom, Japan, Australia and Israel, supporting Pharming’s global expansion strategy
L
eiden,
t
he Netherlands,
May
22, 2026
:
Pharming Group (